About
The
Company
Asep Inc. consolidates two development-stage companies —
Sepset Biosciences and ABT Innovations, both with
shared missions, founders and investors.
Our purpose is to mitigate the global crisis of antibiotic failure by improving patients’ odds of survival and quality of life.
Together, our diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments.
Diagnostic
Offering:
Novel diagnostic assay for the early and rapid risk assessment of sepsis.
Impact:
Dramatically faster test results, for a health crisis where every hour counts.

Therapeutic
Offering:
Patented peptide technology targets infection-causing biofilms and reduces inflammation.
Impact:
Effectively treats antibiotic-resistant infections, where nothing else works.
Offering:
Substrate-independent, antibacterial peptide coatings.
IMPACT:
Vastly improved sterile surfaces for medical instruments and implants.
Our Values
To continually innovate to address the global crisis of antibiotic failure, improving survivability and quality of life for patients.
Mission
To combine the best scientific, development and business teams to provide the best possible care to those suffering with antibiotic-resistant infections.
Our Vision
To become the global market leader in the diagnosis and treatment of antibiotic-resistant infections.
Leadership

Dr. Richard Heinzl
Interim chief Executive Officer, board member
Richard Heinzl is a physician, humanitarian, entrepreneur, and author whose current focus is genomics, artificial intelligence, and healthcare worldwide. Based in New York and Toronto, he is currently CEO of My Next Health Inc., a next–generation functional genomics company. Earlier in his career, Heinzl founded the Canadian chapter of Médecins Sans Frontières/Doctors Without Borders (MSF Canada), which won the Nobel Peace Prize in 1999. Recently, he was Global Medical Director for WorldCare Inc., a Boston-based, Harvard-affiliated virtual medicine company. He is a graduate of McMaster University’s Michael G. DeGroote School of Medicine and completed postgraduate degrees related to global health at Harvard University and the University of Oxford. He is an Emeritus Fellow of the American College of Preventive Medicine. His work and travels have taken him to over 80 countries, and he speaks widely in North America and abroad.
Jacqueline M. Tucker
Chief Financial Officer
Ms. Tucker is the president of J.M. Tucker Professional Corp. The company was established in 1995 in Vancouver, BC, providing audit and related financial services to emerging companies in the resource, bio-medical and high-tech industries. In 2005, Ms. Tucker relocated to Calgary, Alberta, and realigned the company’s areas of practice to include contract Chief Financial Officer services and advisory services to Canadian public companies including financial reporting, disclosure issues, and compliance with securities legislation. During her career, Ms. Tucker has held a number of senior executive officer positions including CEO and CFO with Canadian public companies as well as holding various board positions.
Board of Directors
Derrold Norgaard
DIRECTOR, CHAIR – AUDIT COMMITTEE
Derrold Norgaard is a Fellow of the Chartered Professional Accountants of British Columbia. He held the dual role of Tax Partner and Office Managing Partner at KPMG until 2008. Norgaard’s primary areas of practice include personal tax planning, international tax and corporate taxation. He has authored several articles on Canadian tax planning and has been an instructor in Canadian tax programs for many years. He is a frequent speaker to business groups throughout Canada and Asia.
Dr. Richard Heinzl
Director
Dr. Heinzl is a physician, humanitarian, entrepreneur and author whose current focus is genomics, artificial intelligence and healthcare worldwide. Based in New York and Toronto, he is currently CEO of My Next Health Inc.
Paul Kania
Director
Mr. Kania brings over 20 years of accounting, finance, and corporate governance experience to Asep. He founded PLK Accounting & Finance Inc., providing C-suite leadership and board advisory services to private and public companies. Previously, he served as a Corporate Finance manager at Brookfield Asset Management and an auditor at MNP LLP in Toronto and Berdon LLP in New York.
collaborators/partners
GenomeCanada
iFyber
IQVIA
NMIN
Vetoquinol
We’ve got big plans
Stay in the loop
ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved